Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06607731

Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

Status
Recruiting
Phase
Study type
Observational
Enrollment
11 (estimated)
Sponsor
Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.

Conditions

Interventions

TypeNameDescription
OTHERCollecting data from medical recordsData collected: clinical data (particularly pain), biological data, imaging.

Timeline

Start date
2024-06-25
Primary completion
2024-12-01
Completion
2024-12-01
First posted
2024-09-23
Last updated
2024-10-08

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06607731. Inclusion in this directory is not an endorsement.

Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy (NCT06607731) · Clinical Trials Directory